Compare CVS Health Corp (CVS) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs SkyWest Inc — how do they compare? CVS Health Corp trades at $86.01 (market cap $112.29B), while SkyWest Inc trades at $96.18 (market cap $3.75B). The key difference: CVS Health Corp is far larger — about 29.9× SkyWest Inc's market cap, and CVS Health Corp pays a 3.03% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and SkyWest Inc for 8 Days on average.
| CVS | SKYW | |
|---|---|---|
Market Cap | $112.29B | $3.75B |
Volume | 7,763,676 | 196,324 |
Sector | Health | Industrials |
52-Week High | $110.60 | $115.94 |
52-Week Low | $70.08 | $78.40 |
Typical Hold Time | 83 Days | 8 Days |
Enterprise Value | $174.64B | $5.54B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 9.6 and P/S of 0.94, while maintaining solid profitability with a 9.78% net income margin. Recent earnings have been mixed, with a Q1 2026 beat but a Q2 2026 miss. Positive developments include fleet modernization efforts and expanded flying agreements, though cost pressures remain a concern.
The investment case balances strong analyst support—58.82% recommend Buy with a $112 consensus target—against near-term technical weakness and earnings volatility. Upside potential exists from operational improvements and cash flow growth, but risks include execution on cost management and broader airline industry challenges. The stock presents a value opportunity for patient investors despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
